← Back
$SKYE All transactions

Skye Bioscience, Inc.

▼ SELL

$ Value

$561K

Shares

163,979

Price

$3

Filed

Aug 22

Insider

Name

5AM Partners VII, LLC

Title

CIK

0001873545

Roles

10% Owner

Transaction Details

Transaction Date

2025-08-22

Code

S

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

1,457,064

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. | The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Filing Info

Accession No.

0001415889-25-022806

Form Type

4

Issuer CIK

0001516551

5AM Partners VII, LLC's History

Date Ticker Type Value
2025-08-22 SKYE $561K
2025-08-22 SKYE $22K
2025-08-21 SKYE $209K
2025-08-21 SKYE $8K

Other Insiders at SKYE (90d)

Insider Bought Sold Last
DHILLON PUNIT
Chief Executive Officer
2026-03-31
Schwab Andrew J. 2026-03-31
Jenkins Annalisa 2026-03-31
Smith Karen L. 2026-03-31
Grayson Paul A. 2026-03-31
Twitty Christopher
Chief Scientific Officer
2026-03-31
Charych Deborah H. 2026-03-31
Diep Tuan Tu
Chief Operating Officer
2026-03-31